NL8701163A - Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. - Google Patents
Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. Download PDFInfo
- Publication number
- NL8701163A NL8701163A NL8701163A NL8701163A NL8701163A NL 8701163 A NL8701163 A NL 8701163A NL 8701163 A NL8701163 A NL 8701163A NL 8701163 A NL8701163 A NL 8701163A NL 8701163 A NL8701163 A NL 8701163A
- Authority
- NL
- Netherlands
- Prior art keywords
- peptide
- compounds
- antigen
- autoimmune diseases
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 title claims description 17
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 12
- 230000002917 arthritic effect Effects 0.000 title claims description 10
- 238000003745 diagnosis Methods 0.000 title claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 241000588748 Klebsiella Species 0.000 claims description 4
- 241000186359 Mycobacterium Species 0.000 claims description 4
- 241000589886 Treponema Species 0.000 claims description 4
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 4
- 241000187654 Nocardia Species 0.000 claims description 3
- 241000607768 Shigella Species 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 241000894007 species Species 0.000 claims description 3
- 241000589876 Campylobacter Species 0.000 claims description 2
- 241000588722 Escherichia Species 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 108010077805 Bacterial Proteins Proteins 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 39
- 206010003246 arthritis Diseases 0.000 description 18
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 208000009386 Experimental Arthritis Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 230000003053 immunization Effects 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 230000006698 induction Effects 0.000 description 6
- 201000008827 tuberculosis Diseases 0.000 description 6
- 238000002649 immunization Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010071155 Autoimmune arthritis Diseases 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000186362 Mycobacterium leprae Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 241000187644 Mycobacterium vaccae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003286 arthritogenic effect Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000750676 Bacillus phage Gamma Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 244000133018 Panax trifolius Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100040865 Phospholipase A2 group XV Human genes 0.000 description 1
- 101710127148 Phospholipase A2 group XV Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009003 standardized kity Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8701163A NL8701163A (nl) | 1986-09-09 | 1987-05-14 | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
| NO873699A NO873699L (no) | 1986-09-09 | 1987-09-04 | Polypeptid som er egnet til dempning, behandling og diagnostisering av autoimmune lidelser saasom leddbetennelser. |
| EP87201691A EP0262710B1 (en) | 1986-09-09 | 1987-09-07 | Use of a peptide for the preparation of compositions for the alleviation, treatment and diagnosis of autoimmune diseases, especially arthritic conditions, compounds related to said peptide, micro-organisms expressing said peptide or a compound related to said peptide, as well as pharmaceutical and diagnostic compositions and test kits |
| DE8787201691T DE3781078T2 (de) | 1986-09-09 | 1987-09-07 | Verwendunng eines peptids zur herstellung von zusammensetzungen fuer die linderung, behandlung und diagnose von autoimmunkrankheiten, insbesondere arthritis, zu diesem peptid analoge verbindungen, mikro-organismen, die dieses peptid oder eine zu diesem peptid analoge verbindung produzieren, als auch pharmazeutische und diagnostische zusammensetzungen und test kits. |
| AT87201691T ATE79269T1 (de) | 1986-09-09 | 1987-09-07 | Verwendunng eines peptids zur herstellung von zusammensetzungen fuer die linderung, behandlung und diagnose von autoimmunkrankheiten, insbesondere arthritis, zu diesem peptid analoge verbindungen, mikro-organismen, die dieses peptid oder eine zu diesem peptid analoge verbindung produzieren, als auch pharmazeutische und diagnostische zusammensetzungen und test kits. |
| IL83817A IL83817A (en) | 1986-09-09 | 1987-09-07 | Polypeptide useful for the alleviation, treatment and diagnosis of autoimmune diseases, especially arthritic conditions, compounds related to said peptide, micro-organisms expressing said peptide or a compound related to said peptide, as well as pharmaceutical and diagnostic compositions and test kits |
| AU78000/87A AU601765B2 (en) | 1986-09-09 | 1987-09-07 | Polypeptide useful for the alleviation, treatment and diagnosis of autoimmune diseases, especially arthritic conditions etc., |
| DK467487A DK467487A (da) | 1986-09-09 | 1987-09-08 | Polypeptid, anvendeligt til lindring, behandling og diagnosticering af autoimmunitetssygdomme, isaer arthritis |
| JP62226221A JP2505213B2 (ja) | 1986-09-09 | 1987-09-09 | 自己免疫疾病の治療、診断用ポリペプチド |
| CA000546494A CA1315225C (en) | 1986-09-09 | 1987-09-09 | Polypeptide useful for the allevation, treatment and diagnosis of auto-immune diseases, especially arthritic conditions, etc. |
| US07/946,818 US5268170A (en) | 1986-09-09 | 1992-09-17 | Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8602270A NL8602270A (nl) | 1986-09-09 | 1986-09-09 | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
| NL8602270 | 1986-09-09 | ||
| NL8701163 | 1987-05-14 | ||
| NL8701163A NL8701163A (nl) | 1986-09-09 | 1987-05-14 | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8701163A true NL8701163A (nl) | 1988-04-05 |
Family
ID=26646154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8701163A NL8701163A (nl) | 1986-09-09 | 1987-05-14 | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0262710B1 (no) |
| JP (1) | JP2505213B2 (no) |
| AU (1) | AU601765B2 (no) |
| CA (1) | CA1315225C (no) |
| DE (1) | DE3781078T2 (no) |
| DK (1) | DK467487A (no) |
| IL (1) | IL83817A (no) |
| NL (1) | NL8701163A (no) |
| NO (1) | NO873699L (no) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4952395A (en) * | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| US4976958A (en) * | 1987-02-26 | 1990-12-11 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| NL8703107A (nl) * | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
| ES2051989T3 (es) * | 1988-10-21 | 1994-07-01 | Akzo Nv | Un procedimiento para la manufactura de una inmunotoxina para el tratamiento o profilaxis de una enfermedad autoinmune. |
| US5578303A (en) * | 1989-03-14 | 1996-11-26 | Yeda Research And Development Co. Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
| US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
| US5780034A (en) * | 1989-03-14 | 1998-07-14 | Yeda Research And Development Co. Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents |
| GB8919321D0 (en) * | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
| GB9024320D0 (en) * | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
| AU4762893A (en) * | 1992-07-15 | 1994-02-14 | Rijksuniversiteit Leiden | Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases. |
| DK0700445T3 (da) | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
| DK0751957T3 (da) * | 1994-03-21 | 2004-06-01 | Univ Utrecht | Peptid-fragmenter af mikrobielle stressproteiner og farmaceutisk sammensætning fremstillet deraf til behandling og forebyggelse af inflammatoriske sygdomme |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| IL134341A0 (en) | 1997-08-05 | 2001-04-30 | Stressgen Biotechnologies Corp | Compositions for inducing an immune response containing an hpv protein antigen |
| US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
| JP2003504074A (ja) | 1999-07-08 | 2003-02-04 | ストレスゲン バイオテクノロジーズ コーポレイション | インビトロでのＴｈ１様応答の誘導 |
| EP1253939B1 (en) | 2000-01-14 | 2009-08-05 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
| IL153474A0 (en) | 2000-06-26 | 2003-07-06 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
| US6989146B2 (en) * | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
| PL373675A1 (en) | 2001-02-05 | 2005-09-05 | Stressgen Biotechnologies Corporation | Hepatitis b virus treatment |
| WO2003063759A2 (en) | 2002-01-31 | 2003-08-07 | Peptor Ltd. | Hsp peptides and analogs for modulation of immune responses via antigen presenting cells |
| ES2433915T3 (es) | 2002-05-21 | 2013-12-13 | Irun R. Cohen | Vacunas de ADN que codifican proteínas de choque térmico |
| CU23504A1 (es) | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| WO2006072946A2 (en) | 2005-01-04 | 2006-07-13 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |
| AU2006224216B2 (en) | 2005-03-14 | 2011-12-08 | B.G. Negev Technologies And Applications Ltd. | Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL71683A0 (en) * | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
-
1987
- 1987-05-14 NL NL8701163A patent/NL8701163A/nl not_active Application Discontinuation
- 1987-09-04 NO NO873699A patent/NO873699L/no unknown
- 1987-09-07 IL IL83817A patent/IL83817A/xx unknown
- 1987-09-07 EP EP87201691A patent/EP0262710B1/en not_active Expired - Lifetime
- 1987-09-07 AU AU78000/87A patent/AU601765B2/en not_active Ceased
- 1987-09-07 DE DE8787201691T patent/DE3781078T2/de not_active Expired - Lifetime
- 1987-09-08 DK DK467487A patent/DK467487A/da not_active Application Discontinuation
- 1987-09-09 CA CA000546494A patent/CA1315225C/en not_active Expired - Fee Related
- 1987-09-09 JP JP62226221A patent/JP2505213B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL83817A (en) | 1993-01-31 |
| NO873699L (no) | 1988-03-10 |
| DE3781078D1 (de) | 1992-09-17 |
| DK467487A (da) | 1988-03-10 |
| IL83817A0 (en) | 1988-02-29 |
| JP2505213B2 (ja) | 1996-06-05 |
| JPS63126895A (ja) | 1988-05-30 |
| DE3781078T2 (de) | 1992-12-24 |
| EP0262710A1 (en) | 1988-04-06 |
| CA1315225C (en) | 1993-03-30 |
| NO873699D0 (no) | 1987-09-04 |
| EP0262710B1 (en) | 1992-08-12 |
| AU7800087A (en) | 1988-03-17 |
| DK467487D0 (da) | 1987-09-08 |
| AU601765B2 (en) | 1990-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8701163A (nl) | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. | |
| US5154923A (en) | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions | |
| EP0417271B1 (en) | Diagnosis and treatment of insulin dependent diabetes mellitus | |
| Elias et al. | Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. | |
| Eylar et al. | [31] Myelin basic proteins | |
| DE69738329T2 (de) | Zielrichten von antigenen auf den mhc-klasse i prozessierungsweg mit hilfe eines anthraxtoxin-fusionsproteins | |
| JPH0751509B2 (ja) | 関節炎疾患及び関連症状の軽減、処置及び診断のための組成物 | |
| JP2007000147A (ja) | 微生物ストレスタンパク質のペプチド断片、および該タンパク質もしくは断片の使用 | |
| JPS62228286A (ja) | ボルデテラ・パ−タツシス染色体ＤＮＡのＥｃｏＲＩフラグメント | |
| DE69628336T2 (de) | Behandlung und diagnose helicobacter pylori infektionen | |
| US5578303A (en) | Diagnosis and treatment of insulin dependent diabetes mellitus | |
| JPH06508513A (ja) | マイコバクテリウムタンパク質およびその使用 | |
| US5268170A (en) | Methods of treatment and diagnosis of autoimmune diseases, especially arthritic conditions | |
| JP2003515342A (ja) | シュードモナス・エルジノサ抗原 | |
| Jasin et al. | The antigenicity of some synthetic poly-iminoacids: I. Antigenic properties of poly-L-proline | |
| Hopper | Comparative Studies on Monotypic IgMλ and IgGκ from an Individual Patient: I. Evidence for Shared VH Idiotypic Determinants | |
| EP0320866A2 (en) | A protective immunodominant epitope included in the S1 subunit of pertussis toxin | |
| Rimler | Partial purification of cross-protection factor (s) from Pasteurella multocida | |
| DE69930147T2 (de) | Zwei-schritte-verfahren zur impfung gegen chlamydia | |
| Bouwer et al. | Cytotoxic-T-lymphocyte responses to epitopes of listeriolysin O and p60 following infection with Listeria monocytogenes | |
| DE60035485T2 (de) | IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407 | |
| NL8602270A (nl) | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. | |
| JP2009029825A (ja) | 抗原 | |
| Anteunis | Cytochemical and ultrastructural studies concerning the cell coat glycoproteins in normal and transformed human blood lymphocytes: I. Variations of sialic acid containing glycoproteins subsequent to transformation of T and B lymphocytes by various kinds of stimulating agents | |
| Swanborg | Immunologic response to altered encephalitogenic protein in guinea pigs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |